These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769 [TBL] [Abstract][Full Text] [Related]
3. Infliximab monotherapy for refractory psoriasis: preliminary results. Cassano N; Loconsole F; Amoruso A; Coviello C; Filieri M; Filotico R; Del Vecchio S; Vena GA Int J Immunopathol Pharmacol; 2004; 17(3):373-80. PubMed ID: 15461871 [TBL] [Abstract][Full Text] [Related]
4. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. Schopf RE; Aust H; Knop J J Am Acad Dermatol; 2002 Jun; 46(6):886-91. PubMed ID: 12063486 [TBL] [Abstract][Full Text] [Related]
5. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE; Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614 [TBL] [Abstract][Full Text] [Related]
6. [Infliximab. Role in the treatment of psoriasis]. Mössner R; Reich K Hautarzt; 2005 Sep; 56(9):831-2, 834-8. PubMed ID: 16133635 [TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. O'Quinn RP; Miller JL Arch Dermatol; 2002 May; 138(5):644-8. PubMed ID: 12020227 [TBL] [Abstract][Full Text] [Related]
9. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Weinberg JM Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of severe refractory psoriasis with infliximab]. Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800 [TBL] [Abstract][Full Text] [Related]
11. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160 [TBL] [Abstract][Full Text] [Related]
12. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade)]. Valdés A Mdel P; Schroeder H F; Roizen G V; Honeyman M J; Sánchez M L Rev Med Chil; 2006 Mar; 134(3):326-31. PubMed ID: 16676105 [TBL] [Abstract][Full Text] [Related]
14. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)]. Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920 [TBL] [Abstract][Full Text] [Related]
15. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Chan JJ; Gebauer K Australas J Dermatol; 2003 May; 44(2):116-20. PubMed ID: 12752184 [TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660 [TBL] [Abstract][Full Text] [Related]
17. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454 [TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment of psoriasis in supervised infusion centers: case management experience. Campos Muñoz L; de Unamuno Bustos B; Herranz Pinto P; El Ahmed HH; Ruiz-Villaverde R; Taberner Ferrer R Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S17-24. PubMed ID: 24777572 [TBL] [Abstract][Full Text] [Related]
20. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Van den Bosch F; Kruithof E; Baeten D; De Keyser F; Mielants H; Veys EM Ann Rheum Dis; 2000 Jun; 59(6):428-33. PubMed ID: 10834859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]